New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 14, 2013
11:14 EDTULTA, SUPN, NAV, CTRXOptions with decreasing implied volatility: SUPN CTRX NAV ULTA
News For SUPN;CTRX;NAV;ULTA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 22, 2015
10:03 EDTNAVOn the Fly: Analyst Downgrade Summary
Subscribe for More Information
January 21, 2015
16:32 EDTSUPNSupernus sues TWi for infringement of Oxtellar XR patents
Subscribe for More Information
16:26 EDTNAVNavistar downgraded to Underperform from Market Perform at BMO Capital
Subscribe for More Information
10:01 EDTCTRXOn the Fly: Analyst Initiation Summary
Subscribe for More Information
07:38 EDTCTRXCatamaran initiated with an Overweight at Stephens
Subscribe for More Information
January 16, 2015
17:04 EDTSUPNSupernus sues Par Pharmaceuticals for patent infringement
Supernus Pharmaceuticals announced that it sued generic drug makers Par Pharmaceutical Companies, and Par Pharmaceutical, collectively known as Par, for infringement of four patents covering its antiepileptic drug Trokendi XR. Supernus' United States Patents Nos. 8,298,576, 8,298,580, 8,663,683 and 8,877,248 cover once-a-day topiramate formulations and methods of treating seizures using those formulations. Patent protection for Trokendi XR expires no earlier than 2027. The complaint, filed in the U.S. District Court for the District of New Jersey, alleges that Par infringed Supernus' Trokendi XR patents by submitting to the FDA an Abbreviated New Drug Application, ANDA, seeking to market a generic version of Trokendi XR prior to the expiration of Supernus' patents. Filing its complaint within 45 days of receiving Par's Paragraph IV certification notice entitles Supernus to an automatic stay preventing the FDA from approving Par's ANDA for 30 months.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use